GRAL vs NTRA
GRAL: GRAIL is a pioneer in multi-cancer early detection, developing blood-based tests designed to identify multiple types of cancer at earlier, more treatable stages. NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications.
Side-by-side fundamentals
| Metric | GRAL | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $132.61 | $390.79 | |
| Market cap | $5.9B | $56.3B | |
| Net margin FY2025, SEC XBRL | -277.5% | -9.0% | NTRA higher |
| Operating margin FY2025, SEC XBRL | -382.0% | -13.4% | NTRA higher |
| ROE FY2025, SEC XBRL | -15.8% | -12.2% | NTRA higher |
| ROA FY2025, SEC XBRL | -14.0% | -8.7% | NTRA higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.04 | GRAL lower |
| Revenue growth (YoY) as of 2026-09-03 | +23.1% | +37.8% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +25.7% | +41.1% | NTRA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.57 | 1.29 | |
| 1-year return as of 2026-10-08 close | +82.2% | +127.1% | NTRA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.